Scholars@Duke
Daniel Philip Nussbaum

Daniel Philip Nussbaum

Associate Professor of Surgery
Surgical Oncology
daniel.nussbaum@duke.edu
DUMC 2612, Durham, NC 27710
DUMC 2612, Durham, NC 27710

Scholarly Works - Conferences

Social Vulnerability as a Neighborhood-Level Determinant of Pancreatic Cancer Survivorship: A National Analysis of Veterans Affairs Patients.

Conference Ann Surg Oncol · February 2026 BACKGROUND: Veterans Affairs (VA) patients participate within the largest USA equal-access healthcare system, though still experience cancer mortality disparities by social determinants. The Social Vulnerability Index (SVI)-measuring community poverty, min ... Full text Link to item Cite

Abstract B074: scRNA-seq from FFPE tissue resolves the tumor microenvironment of intraductal papillary mucinous neoplasms

Conference Cancer Research · September 28, 2025 AbstractIntraductal papillary mucinous neoplasms (IPMN) are precancerous cysts representing the only radiographically identifiable precursor to pa ... Full text Cite

Abstract A009: Characterizing the pre-metastatic liver in PDAC patients using scRNA-seq of FFPE tissue

Conference Cancer Research · September 28, 2025 AbstractPancreatic ductal adenocarcinoma (PDAC) remains an essentially incurable disease. Even among patients considered for curative-intent surge ... Full text Cite

Perioperative and Oncologic Outcomes of Hepatic Arterial Infusion (HAI) Pump Chemotherapy for Patients with Unresectable Colorectal Liver Metastases at an Expanding HAI Program.

Conference Ann Surg Oncol · February 2025 BACKGROUND: Hepatic arterial infusion (HAI) is an established treatment for patients with unresectable colorectal liver metastases (uCRLM). Until recently, HAI was only performed at a limited number of centers. We previously reported early outcomes suggest ... Full text Link to item Cite

Uncovering the role of oncogenic HER2 variants as drivers of pancreatic cancer.

Conference Journal of Clinical Oncology · February 2025 772Background: The therapeutic resistance of pancreatic ductal adenocarcinoma (PDAC) to conventional cytotoxic therapy unders ... Full text Cite

Abstract B052: Single-cell and spatial analysis of the immune landscape unveils a subset of potentially tumor-reactive T cells in patients with localized PDAC

Conference Cancer Research · September 15, 2024 AbstractEven in its localized stages, pancreatic ductal adenocarcinoma (PDAC) is virtually incurable, characterized by early dissemination and disease recurrence. The liver is the most common site of metasta ... Full text Cite

Abstract C004: A window-of-opportunity trial using neoadjuvant hepatic artery chemotherapy for patients with localized pancreas cancer: Interim analysis of safety and feasibility

Conference Cancer Research · September 15, 2024 AbstractLess than 20% of patients diagnosed with pancreatic cancer will present with localized disease and receive both resection and systemic therapy. Within this group of patients, actual 10-year survival ... Full text Cite

Fragmented Care in Stage II and III Gastric and Esophageal Cancer

Conference ANNALS OF SURGICAL ONCOLOGY · March 2024 Link to item Cite

Abstract B022: A platform to characterize hepatic immunity reveals variation in hepatic infiltration of tumor expanded T cells in “localized” PDAC

Conference Cancer Research · January 16, 2024 AbstractEven in its earliest stages, pancreatic ductal adenocarcinoma (PDAC) is an essentially incurable disease due to the presence of disseminated, yet radiographically occult cancer cells in the setting o ... Full text Cite

The Impact of Age in the Treatment of Patients with Localized Rectal Cancer - Survival Outcomes from the National Cancer Database

Conference British Journal of Surgery · June 9, 2023 AbstractBackgroundMultimodal therapy for localized rectal cancer (RC), including (neo-)adjuvant systemic therapy and surgery, has impr ... Full text Cite

Evolution in Management of Upfront Treatment For Desmoid Tumors

Conference ANNALS OF SURGICAL ONCOLOGY · March 2023 Link to item Cite

Impact of Tumor Size and Management on Survival in Gastric GIST

Conference ANNALS OF SURGICAL ONCOLOGY · March 2023 Link to item Cite

Multidimensional Immunophenotyping of Intraductal Papillary Mucinous Neoplasms Reveals Novel T Cell and Macrophage Signature.

Conference Ann Surg Oncol · November 2022 BACKGROUND: Intraductal papillary mucinous neoplasms (IPMN) are the only radiographically identifiable precursor to pancreatic adenocarcinoma, yet little is known about how these lesions progress to cancer. Inflammation has been associated with dysplastic ... Full text Link to item Cite

Impact of minimally invasive gastrectomy on use of and time to adjuvant chemotherapy for gastric adenocarcinoma.

Conference J Surg Oncol · March 2020 BACKGROUND: Chemotherapy improves outcomes in patients with resectable gastric cancer. Minimally invasive gastrectomy (MIS) rates are increasing, though the impact of MIS on postoperative chemotherapy remains uncertain. This study examines the impact of MI ... Full text Link to item Cite

Adjuvant Chemotherapy Improves Survival Following Resection of Locally Advanced Rectal Cancer with Pathologic Complete Response.

Conference J Gastrointest Surg · August 2019 BACKGROUND: Controversy exists over the use of adjuvant chemotherapy for locally advanced (stages II-III) rectal cancer (LARC) patients who demonstrate pathologic complete response (pCR) following neoadjuvant chemoradiation. We conducted a retrospective an ... Full text Link to item Cite

Measuring the Quality of Gastric Cancer Care in the United

Conference ANNALS OF SURGICAL ONCOLOGY · February 1, 2018 Link to item Cite

Lymph node yield during pancreatic surgery - a distinct view

Conference SWISS MEDICAL WEEKLY · September 12, 2017 Link to item Cite

Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: An analysis of 18 243 patients.

Conference J Surg Oncol · August 2017 BACKGROUND: Neoadjuvant therapy has theoretical benefits for pancreatic cancer; however, its association with perioperative outcomes remains controversial. This study sought to evaluate variation in use of neoadjuvant therapy and outcomes following pancrea ... Full text Link to item Cite

Going the Extra Mile: Improved Survival for Pancreatic Cancer Patients Traveling to High-volume Centers.

Conference Ann Surg · August 2017 OBJECTIVE: This study compares outcomes following pancreaticoduodenectomy (PD) for patients treated at local, low-volume centers and those traveling to high-volume centers. BACKGROUND: Although outcomes for PD are superior at high-volume institutions, not ... Full text Link to item Cite

Minimally Invasive Pancreaticoduodenectomy Does Not Improve Use or Time to Initiation of Adjuvant Chemotherapy for Patients With Pancreatic Adenocarcinoma.

Conference Ann Surg Oncol · March 2016 BACKGROUND: The modifiable variable best proven to improve survival after resection of pancreatic adenocarcinoma is the addition of adjuvant chemotherapy. A theoretical advantage of minimally invasive pancreaticoduodenectomy (MI-PD) is the potential for gr ... Full text Link to item Cite

Lymph Node Yield Between Open and Laparoscopic Portal Lymphadenectomy

Conference ANNALS OF SURGICAL ONCOLOGY · February 1, 2016 Link to item Cite

Abstract 5465: Systematic interrogation of druggable pathways in pancreatic adenocarcinomas using pooled gene-knockdown lentiviral libraries

Conference Cancer Research · August 1, 2015 AbstractDespite significant advances in the development of cancer treatment in the last 20 years the best available therapies have marginally improved the survival rate of treated pancreatic cancer patients ... Full text Cite

Systematic interrogation of druggable pathways in pancreatic adenocarcinoma

Conference MOLECULAR BIOLOGY OF THE CELL · December 1, 2014 Link to item Cite

Defining the learning curve for team-based laparoscopic pancreaticoduodenectomy.

Conference Ann Surg Oncol · November 2014 BACKGROUND: The purpose of this study was to define the learning curves for laparoscopic pancreaticoduodenectomy (LPD) with and without laparoscopic reconstruction, using paired surgical teams consisting of advanced laparoscopic-trained surgeons and advanc ... Full text Link to item Cite